1. Background {#sec1}
=============

Ischemic heart disease (IHD) remains a global health concern, and acute myocardial infarction continues to be a leading cause of death \[[@B1]\]. Restriction of coronary blood supply leads to myocardial infarction which is the primary determinant of disease prognosis \[[@B1]\]. The infarct size and disease outcome can remarkably be improved by restoration of blood flow by reperfusion \[[@B2]\]. However, reperfusion itself can be devastating resulting in significant damage within the ischemia-affected area \[[@B2]\]. Several cardioprotective strategies have been developed to limit the destructive effects of ischemia/reperfusion (I/R) injury on the myocardium. These include, but are not limited to, the application of brief sublethal ischemic episodes at the beginning of reperfusion on-site or a distant vascular bed (ischemic postconditioning and remote ischemic postconditioning, respectively) \[[@B3], [@B4]\]. More recently, a modification of the remote postconditioning maneuver has been introduced which involves changing myocardial stretch pattern via remote electrical stimulation of the heart chambers (pacing postconditioning (PPC)) \[[@B5]\]. We have reported that PPC is an effective protective postconditioning maneuver against I/R injury in experimental animals \[[@B5]--[@B7]\]. We have further investigated the molecular mechanisms involved in PPC-induced cardiac protection \[[@B8]--[@B10]\]. The first clinical application of the PPC maneuver demonstrated significant decrease in infarct size in ST-segment elevation myocardial infarction (STEMI) patients \[[@B11]\]. This, however, was accompanied by arterial and ventricular fibrillation \[[@B11]\]. Additional clinical studies would, therefore, require further technical optimization and more comprehensive consideration of various clinical scenarios existing in MI patients that could potentially attenuate the cardioprotective properties of PPC or may cause undesirable side effects.

Aging-induced structural and functional changes in the cardiovascular system were linked to increased incidence of CVD in the elderly \[[@B12]\]. Aging is a common risk factor in MI patients and reduces patients\' tolerance to ischemia and imposes a significant impact on disease prognosis \[[@B13], [@B14]\]. Ischemic postconditioning-induced cardiac protection was attenuated in senescent mice \[[@B15]\]. The efficiency of PPC-induced cardiac protection in aging remains to be established.

Increased susceptibility of hypertrophied heart to ischemia \[[@B16]\] and postischemic arrhythmias \[[@B17]\] were previously reported. Available evidence on the efficiency of ischemic postconditioning strategies in attenuating ischemic injury in the presence of LVH is contradictory, possibly due to use of different LVH models \[[@B18], [@B19]\]. LVH has been associated with increased mortality from MI \[[@B20]\]. Thus, the identification of effective maneuvers for the protection of hypertrophied hearts is essential.

Patients with type 1 and type 2 diabetes are prone to cardiovascular diseases \[[@B21]\], and IHD remains to be a significant source of morbidity and mortality in these patients. Increased risk of ischemic events and poor recovery after an acute MI event were demonstrated in diabetic patients \[[@B22]\]. Inconsistent data from experimental models were reported on the susceptibility of diabetic heart to ischemic injury \[[@B23], [@B24]\]. The available data on the efficacy of postconditioning strategies in protecting the diabetic heart from ischemic injury are equivocal \[[@B25], [@B26]\], possibly due to the use of different experimental models and conditioning protocols. We have previously reported that seven cycles of alternating left and right ventricular pacing for 30 seconds each to a minimum of 200 seconds did not protect diabetic rabbit hearts from I/R injury \[[@B25]\]. Nonetheless, the effect of PPC in protecting diabetic rodent hearts against ischemic injury has not been previously given consideration.

There is a notable increase in the incidence of IHD in pregnancy in the recent years, possibly due to the increasing maternal age, higher prevalence of cardiac risk factors, and change of some social habits like smoking \[[@B27]\]. Enhanced risk of IHD and deteriorated prognosis were reported in pregnancy \[[@B27]\]. Pregnancy causes significant changes in cardiac hemodynamics which could ultimately lead to IHD \[[@B28]\]. Also, increased cardiac workload and increased myocardial oxygen demand during pregnancy may cause severe IHD \[[@B29]\]. Although many treatment regimens were used in treating IHD during pregnancy, postconditioning data in animal models or clinical studies are lacking \[[@B6], [@B30]\].

In this study, we were set to investigate the efficacy of PPC maneuver in protection against I/R injury in male and female rats in the presence of clinically relevant scenarios including aging, LVH, diabetes mellitus, and pregnancy.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

All materials were purchased from Sigma-Aldrich (St. Louis, Missouri) unless stated otherwise.

2.2. Animals and Procedures {#sec2.2}
---------------------------

Animal treatments and handling were performed according to the laboratory animal care guidelines of Kuwait University in accordance with International Guide for the Care and Use of Laboratory Animals (Eighth edition, 2011). In this study, we followed methods and procedures used in our previous studies \[[@B6], [@B25], [@B31]\]. Age-matched male and female Sprague--Dawley rats weighing between 210 and 370 g were used in this study. The rats were maintained at 22°C on a 12-hr light/dark cycle (7 am--7 pm), and water and food were provided ad libitum. A total of 128 rats were subdivided into 16 groups (*n*=8 per group) and were subjected to 4 different experimental protocols, as summarized in ([Figure 1](#fig1){ref-type="fig"}). All rats used in the study are 20 weeks old unless otherwise stated. To study the effects of aging and LVH, hearts from 20-month-old male and female SD rats and spontaneously hypertensive rats (SHR) were used, respectively. For experiments on diabetic hearts, diabetes was induced by a single intraperitoneal injection of 55 mg/kg body weight streptozotocin (STZ) as described previously \[[@B32]\]. Basal glucose levels were determined before the STZ injection and 48 hr after injection. Blood glucose concentration of 250 mg/dL was used as a cutoff value. Rats with blood glucose concentrations more than 250 mg/dL were declared diabetic while rats that did not meet this criterion were excluded from the study \[[@B33]\]. The animals\' diabetic state was re-assessed six weeks later, just before sacrifice. For pregnancy studies, rats were mated overnight. The next day, vaginal smears were examined for the presence of sperms. Females with sperm-positive smear were identified as pregnant and designated day 0 of pregnancy as described previously \[[@B34]\]. These rats were weighed and individually housed in Plexiglas cages undisturbed until day 19 or 21 of gestation when they were sacrificed. 19 and 21 gestation days were selected based on the critical changes in the pregnancy progress in these animals \[[@B35]\].

Anesthesia was administered via an intraperitoneal injection of sodium pentobarbital (60 mg/kg). Heart cannulation and perfusion were performed as described previously \[[@B6]\]. Briefly, the isolated heart was retrogradely perfused with freshly prepared Krebs--Henseleit buffer. Oxygenation was performed using a mixture of CO~2~ (5%) and O~2~ (95%) at a temperature of 37.0 ± 0.5°C. Heart instrumentation included placing pacing electrodes on the right atrium (RA) appendage to maintain physiological heartbeats. Regional ischemia was induced by occluding the left coronary artery for 30 min. Under the basal control conditions, the preload was held constant at 6 mmHg. The perfusion pressure (PP) was held constant at 50 mmHg throughout the experimental procedure in all protocols. The PP was measured immediately downstream of the flow probe from a branch of the aortic cannula using a Statham pressure transducer (P23 Db). Constant PP was ensured electronically using the perfusion assembly (Module PPCM type 671, Hugo Sachs Elektronik, Harvard Apparatus GmbH, Germany), an effective system for accurate adjustment of PP between 5 mm Hg and 150 mm Hg with an accuracy of ±1 mmHg.

2.3. Study Protocol {#sec2.3}
-------------------

All hearts were subjected to 30 min of ischemia produced by left coronary artery occlusion as described previously by Khalaf et al. \[[@B31]\]. Briefly, the left coronary artery was encircled by a snare approximately 0.5 cm below the atrioventricular (AV) groove, and a small rigid plastic tube was positioned between the heart and the snare to ensure complete occlusion of the coronary artery. Afterward, the hearts were reperfused for 30 min. Control hearts were subjected to I/R injury without any further treatment. The PPC involved three alternate RA and LV pacing episodes for 30 sec each. The on-and-off pacing cycles were selected based on our previous studies \[[@B10], [@B25]\]. The pacing electrode was fixed to the posterior basal LV wall and connected to a pacemaker set to the required pacing frequency. Simultaneous AV pacing (AV interval = 0 ms) was used for LV pacing to ensure complete ventricular activation in response to stimulation from the pacing electrode.

2.4. Evaluation of Heart Function {#sec2.4}
---------------------------------

Left ventricular hemodynamics, contractility, and coronary-vascular dynamics were evaluated during stabilization, ischemia, and reperfusion periods. The LV dynamics were determined throughout the experiment by assessing the LV end-diastolic pressure (LVEDP), the maximum developed pressure (DPmax), and LV contractility (+dP/dt or −dP/dt). The coronary vascular dynamics were evaluated by assessing coronary flow (CF) and coronary vascular resistance (CVR). Cardiovascular functions were measured as previously described \[[@B6], [@B25], [@B31]\]. Briefly, a water-filled latex balloon was placed and secured in the LV cavity. The balloon was attached to a pressure transducer and a direct current bridge amplifier (DC-BA) equipped with a pressure module (DC-BA type 660, Hugo-Sachs Electronik, Germany) and interfaced to a personal computer for online monitoring of DPmax. The LVDP data were derived from online acquisition of LVEDP using the Max-Min module (Number MMM type 668, Hugo Sachs Elektronik, Harvard Apparatus GmbH, Germany), which converts the output from the DC-BA to DPmax by subtracting LVEDP.

CF was continuously measured using an electromagnetic flow probe attached to the inflow of the aortic cannula interfaced to a personal computer as described previously in Khalaf et al. \[[@B31]\]. The continuous monitoring of CF in ml/min was digitally monitored using the software developed by Hugo-Sachs (Hugo-Sachs Electronik, Germany) specifically for this purpose and was manually verified via the timed collection of the coronary effluent. The CVR and hemodynamic data were recorded every 10 sec using an online data acquisition program (Isoheart software V 1.524-S, Hugo-Sachs Electronik, Germany). At the end of each experiment, the heart was snap-frozen in liquid nitrogen and stored at −80°C for further analysis.

2.5. Evaluation of Cardiac Injury by Measurements of Infarct Size and Cardiac Enzymes Levels {#sec2.5}
--------------------------------------------------------------------------------------------

The infarct size was determined by triphenyltetrazolium chloride (TTC) staining. Hearts were collected after 30 min of reperfusion and stored overnight at −20°C. The next day, each heart was sliced into 4-5 pieces from its apex to base along the long axis. The slices were then incubated for 15 min in 1% TTC solution in isotonic phosphate buffer (pH 7.4) at 37°C and fixed in 4% formaldehyde. Images were taken using Nikon camera. Red and pale unstained areas of every slice were indicated manually on the image using Leica ImageJ (Image J, Wayne Rasb and National Institute of Health, USA). The percentage infarct area was calculated relative to total LV area. Cardiomyocyte injury was evaluated by measuring creatine kinase (CK) and lactate dehydrogenase (LDH) release in the coronary effluent during the reperfusion period as previously described \[[@B36]\].

2.6. Data Analysis {#sec2.6}
------------------

Data were analyzed by two-way analysis of variance (ANOVA) followed by the least significant difference (LSD) post hoc analysis using SPSS software. Comparisons were performed between group means and the mean for their respective controls. The data were presented as the mean ± standard error of the mean and differences were considered statistically significant at *P* \< 0.05.

3. Results {#sec3}
==========

3.1. PPC Maneuver Provided Cardiac Protection in Aged Female but Not in Male Rats {#sec3.1}
---------------------------------------------------------------------------------

To address the role of age and gender, the effectiveness of PPC in protecting against I/R injury was evaluated in young (four months) and old (twenty months) male and female rats. There were no significant differences in the heart or body weights corrected to tibia length (mg/mm and g/mm, respectively) between young or old males and females. Heart functions were evaluated by the recovery of LV dynamics (DPmax and LVEDP), LV contractility (+dP/dt or −dP/dt), and coronary vascular dynamics (CF and CVR). Baseline changes in the LV dynamics and coronary vascular dynamics during baseline RA pacing were similar in young and aged male and female rats. Index Ischemia resulted in a significant (*P* \< 0.001) deterioration in LV dynamics and coronary vascular dynamics compared to baseline ([Figure 2](#fig2){ref-type="fig"}). The vulnerability of hearts isolated from aged male and female rats to I/R injury was not significantly different from hearts isolated from younger male and female rats ([Figure 2](#fig2){ref-type="fig"}). The PPC intervention significantly (*P* \< 0.05) improved LV dysfunction as evidenced by enhanced DPmax and reduced LVEDP in hearts isolated from aged female rats but not aged male rats (Figures [2(a)](#fig2){ref-type="fig"} and [2(b)](#fig2){ref-type="fig"}). In aged rats, PPC significantly improved coronary vascular dynamics, as indicated by enhanced CF and reduced CVR (*P* \< 0.01) (Figures [2(c)](#fig2){ref-type="fig"} and [2(d)](#fig2){ref-type="fig"}), and improved myocardial contractility (*P* \< 0.01) only in hearts isolated from females ([Table 1](#tab1){ref-type="table"}). Consistent with the physiological data on cardiac functions, PPC significantly decreased the levels of cardiac enzymes (*P* \< 0.01) and the myocardial infarct size (*P* \< 0.01) in hearts from old female but not male rats ([Figure 3(a)](#fig3){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}). Taken together, the physiological, biochemical, and histological data indicate that PPC is an effective cardioprotective method in hearts isolated from young male and female rats and in hearts isolated from old female but not aged male rats.

3.2. PPC-Induced Cardiac Protection Is Revoked in Males with Left Ventricular Hypertrophy {#sec3.2}
-----------------------------------------------------------------------------------------

In this set of experiments, we investigated the effect of LVH on the heart tolerance to ischemic injury and the effectiveness of PPC maneuver in its protection against I/R injury. Body weight corrected to tibia length was significantly (*P* \< 0.05) higher in SHR males (289.73 ± 23.77) relative to the females (215.25 ± 2.73). Moreover, hearts of SHR males showed hypertrophy as indicated by a significant (*P* \< 0.01) increase in heart weight corrected to tibia length (males, 0.39 ± 0.02; females, 0.34 ± 0.01). PPC maneuver was protective in nonhypertrophied hearts from males and females (Figures [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}; Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). Moreover, PPC did not induce a significant reduction in infarct size ([Figure 2(b)](#fig2){ref-type="fig"}) or cardiac enzyme release ([Table 2](#tab2){ref-type="table"}). Interestingly however, PPC significantly improved left ventricular and coronary vascular dynamics (*P* \< 0.001) ([Figure 4](#fig4){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}), reduced infarct size (*P* \< 0.001) ([Figure 2(b)](#fig2){ref-type="fig"}), and cardiac enzyme release (*P* \< 0.01) ([Table 2](#tab2){ref-type="table"}) in nonhypertrophied hearts from SHR females suggesting that the effectiveness of PPC as a cardioprotective maneuver is compromised in hypertrophied hearts.

3.3. Diabetes Mellitus Revokes the Cardioprotective Effects of PPC in Male and Female Rats {#sec3.3}
------------------------------------------------------------------------------------------

Diabetes mellitus did not have a significant effect on cardiac sensitivity to I/R injury (Figures [3](#fig3){ref-type="fig"} and [5](#fig5){ref-type="fig"}; Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}). PPC did not induce significant improvements in the LV dynamics (Figures [5(a)](#fig5){ref-type="fig"} and [5(b)](#fig5){ref-type="fig"}), LV contractility ([Table 1](#tab1){ref-type="table"}), or coronary vascular dynamics (Figures [5(c)](#fig5){ref-type="fig"} and [5(d)](#fig5){ref-type="fig"}) in hearts isolated from diabetic male and female rats. Furthermore, the presence of diabetes abrogated PPC-induced reduction in infarct size and release of cardiac enzymes following I/R injury equally in male and female rats ([Figure 3(c)](#fig3){ref-type="fig"} and [Table 2](#tab2){ref-type="table"}), suggesting that under the conditions tested, PPC is not an efficient cardioprotective method in the diabetic rats.

3.4. PPC-Induced Cardiac Protection Is Preserved in Pregnant Rats {#sec3.4}
-----------------------------------------------------------------

To address the effectiveness of PPC in the protection against I/R injury during pregnancy, hearts from nonpregnant and pregnant females at 19 and 21 days of gestation were subjected to I/R injury-followed PPC. The sensitivity of hearts from pregnant rats at 19 and 21 days of gestation to I/R injury was not significantly different from that of hearts isolated from nonpregnant rats. PPC significantly normalized LV dynamics (*P* \< 0.01), LV contractility (*P* \< 0.001), and vascular dynamics (*P* \< 0.01) in nonpregnant and pregnant rats ([Figure 6](#fig6){ref-type="fig"} and [Table 1](#tab1){ref-type="table"}). This effect was further confirmed by significant reductions in the infarct size (*P* \< 0.001) ([Figure 3(d)](#fig3){ref-type="fig"}) and cardiac enzyme levels (*P* \< 0.01; [Table 2](#tab2){ref-type="table"}). These data indicate for the first time that PPC is an effective cardioprotective maneuver against I/R injury in pregnant rats.

4. Discussion {#sec4}
=============

In the present study, we investigated the sensitivity of hearts isolated from male and female rats with clinically relevant scenarios (aging, LVH, diabetes mellitus, and pregnancy) to ischemic injury and the efficacy of PPC maneuver in protecting these hearts against I/R injury. We demonstrate that aging, LVH, diabetes mellitus, and pregnancy do not affect heart sensitivity to ischemic injury. Furthermore, our data suggest the existence of a novel gender-related discrepancy in PPC-induced cardiac protection in aged and spontaneously hypertensive rats. Heart protection in these animals was exclusively restricted to females. This, however, was not observed in diabetic rats. PPC-induced cardiac protection was revoked equally in diabetic male and female rats. Finally, we demonstrate, for the first time that PPC is an effective cardioprotective maneuver in pregnant rats ([Figure 7](#fig7){ref-type="fig"}).

The first clinical application of PPC was conducted by the Waltenberger and Prinzen groups when they demonstrated encouraging results on the potency of PPC in reducing the infarct size in STEMI patients. This, however, was accompanied by atrial and ventricular fibrillation in about 23% of the population, suggesting the requirement of additional technical optimization \[[@B11]\]. We realize that the successful clinical application of PPC maneuver would, therefore, require a detailed, in-depth analysis of various clinical scenarios existing in MI patients.

The protective effects of ischemic postconditioning were attenuated in aged mice \[[@B37]\]. We have therefore tested if PPC remains effective in protecting hearts from aged male and female rats against I/R injury. Our data suggest that aging does not enhance cardiac sensitivity to ischemic injury. Consistent with our previous data in rabbits, PPC was equally protective in younger male and female rats \[[@B25]\]. In aged rats, however, PPC was protective in a gender-specific manner. PPC protected the hearts isolated from 20-month-old female rats but not from male rats against I/R injury. The observed resistance of aged male rats to cardioprotection is consistent with other studies \[[@B38], [@B39]\]. The exact reason(s) behind gender-related discrimination in cardioprotection is not understood. Several functional alterations were reported in intact hearts and in cardiomyocytes isolated from aged males. Dysfunctional regulation of mitochondrial permeability transition pore (mPTP) opening has been implicated in the loss of the cardioprotective effects of cyclosporine A in aged male cardiomyocytes \[[@B38]\]. Oxidative stress-induced mitochondrial damage was further reported in aged male hearts during ischemia resulting in mitochondria-derived cardiomyocytes injury \[[@B40]\]. Moreover, a significant increase in myocardial protein oxidation was reported in aged male hearts relative to younger controls \[[@B41]\]. Presence of basic lower levels of oxidants and higher levels of antioxidants in the female heart may explain the better protection to the female heart compared to male \[[@B42]\] which is attributed to the different nature of the mitochondrial functioning in male and female hearts \[[@B43]\]. Female hearts were proven to have higher levels of the protective phosphorylated AKT, GSK-3*β*, PKC, and anti-apoptotic factor BCl-2 \[[@B42]\]. Increased levels of the protective phosphorylated AKT, glycogen synthase kinase 3*β* (GSK-3*β*), PKC, and anti-apoptotic factor BCl-2 were reported in hearts from female rodents \[[@B42]\]. Moreover, alterations in cardiac inflammasome with aging could contribute to the observed resistance of aged male hearts to PPC-induced cardiac protection. Enhanced myocardial gene expression of proinflammatory cytokines was reported in animals \[[@B44]\] and clinical studies \[[@B45]\]. Collectively, this could potentially explain a lack of PPC-induced cardiac protection in males. Although protection to female rats could be due to the presence of the female hormone estrogen \[[@B6], [@B46]\], the exact cardioprotective factors conferring protection to females remain to be identified. A side-by-side comparison between males and females is required to identify possible female-specific cardioprotective factor(s).

Our data suggest that LVH does not increase cardiac sensitivity to ischemic injury. Moreover, we demonstrate that hearts from aged, 20-month-old, spontaneously hypertensive male rats are resistant to PPC-mediated cardioprotection. This was not the case in females where hearts were not hypertrophied and were responsive to PPC-induced cardiac protection as evident by reduction in the infarct size and cardiac enzyme release and normalization of contractility and coronary measures. We have previously demonstrated that estrogen receptor-beta protected murine female hearts from LVH \[[@B47]\]. The resistance of hypertrophied male hearts to PPC-mediated cardiac protection is consistent with other studies investigating the cardioprotective effects of captopril postconditioning \[[@B18], [@B19]\]; however, contrasting finding was also reported \[[@B48]\]. Attenuated signaling via reperfusion injury salvage kinase (RISK) GSK-3*β* \[[@B49]\] and PI3K \[[@B50]\] were proposed as possible mechanisms of resistance to cardioprotection in hypertrophied hearts.

Here, we report that diabetes mellitus abolishes PPC-induced cardiac protection in a gender-independent manner. The finding that male and female hearts are equally affected by diabetes mellitus possibly suggests that cellular, metabolic, and physiological changes induced by diabetes are so dramatic that cannot be compensated for by factor(s) usually protecting female hearts against I/R injury. Diabetes-induced alterations in intracellular signaling pathways including the PI3K/Akt/GSK-3*β* pathway and enhanced inflammation and oxidative stress were suggested as possible underlying mechanisms for the lack of protection \[[@B51]--[@B54]\]. Finally, taking into consideration the pronounced effects of diabetes mellitus on cardiac functions and the signaling pathways of postconditioning protection, the identification of an effective cardioprotective maneuver(s) in the diabetics remains essential.

We demonstrate that pregnancy does not affect the sensitivity of hearts to ischemic injury and PPC stands as an effective maneuver in reducing the infarct size and cardiac enzyme release and normalizing LV contractility and hemodynamics in hearts from pregnant rats. This could be due to pregnancy-induced increase in estrogen levels \[[@B55]\] which was reported to be cardioprotective. Estrogen-mediated cardiac protection involved inhibition of L-type calcium channel, opening of mito-KATP \[[@B56]--[@B58]\], and activation of mediators of the RISK pathway \[[@B59]\]. Nevertheless, the exact involvement of estrogen in PPC-induced cardiac protection in pregnant rats\' hearts remains to be directly tested.

A potential limitation of this study is that the underlying molecular mechanisms were not investigated. The reason for that is the previous intensive studies conducted on the signaling pathways of postconditioning (RISK and SAFE pathways). These pathways were proven to be involved in the protection of almost all conditioning studies. The lack of heart protection presented in this study could be due to the alteration or remodeling of these signaling pathways by the clinical scenarios which revoked the protection. The signaling pathways of postconditioning protection reported to date in the literature explain the possible inducers for the protection and the lack of protection. We suggest some studies to unravel the alteration and remodeling of signaling pathways caused by comorbidities and other clinical scenarios.

We conclude that IHD in the presence of clinically relevant scenarios including aging, LVH, diabetes mellitus, and pregnancy does not affect cardiac sensitivity to ischemic injury. However, the efficacy of PPC as an effective cardioprotective maneuver is gender-dependent in aged and spontaneously hypertensive rats. PPC protected pregnant rats and loses its cardioprotective properties in diabetic rats in both genders equally.
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![Illustration of the protocols and experimental groups used in the study. LVH, left ventricle hypertrophy.](CRP2019-3403959.001){#fig1}

![Effects of PPC on left ventricular and coronary vascular dynamics in hearts isolated from young and aging rats. PPC-mediated protection of the heart against I/R injury in hearts isolated from 20-month-old male and female rats (*n*=6 per group). Postischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means ± SEM. PPC, pacing postconditioning. ^*∗*^*P* \< 0.01 compared to the respective control. ^†^*P* \< 0.01 compared to the ischemic period.](CRP2019-3403959.002){#fig2}

![Histological assessment of ischemic injury. Infarct size presented area as a percentage of left ventricle area in the experimental models of aging (a), left ventricular hypertrophy (b), diabetes mellitus (c), and pregnancy (d). PPC, pacing postconditioning. ^*∗*^*P* \< 0.01 compared to the respective control.](CRP2019-3403959.003){#fig3}

![Effects of PPC on left ventricular and coronary vascular dynamics in hypertrophied and nonhypertrophied hearts. PPC-mediated protection in hearts with left ventricle hypertrophy (*n*=6 per group). Postischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means ± SEM. PPC, pacing postconditioning. ^*∗*^*P* \< 0.01 compared to the respective control. ^†^*P* \< 0.01 compared to the ischemic period.](CRP2019-3403959.004){#fig4}

![Effects of PPC on left ventricular and coronary vascular dynamics hearts isolated from nondiabetic and diabetic rats. PPC-mediated protection in hearts isolated from diabetic male and female rats (*n*=6 per group). Postischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means ± SEM. Ctr, control; PPC, pacing postconditioning. ^*∗*^*P* \< 0.01 compared to the respective control. ^†^*P* \< 0.01 compared to the ischemic period.](CRP2019-3403959.005){#fig5}

![Effects of PPC on left ventricular and coronary vascular dynamics in hearts isolated from nonpregnant and pregnant rats. PPC-mediated protection in hearts isolated from pregnant rats at 19 or 21 gestation days (*n*=6 per group). Postischemic recovery from the dysfunction of the heart: (a) DPmax; (b) LVEDP; (c) CF; and (d) CVR. The data were computed at 30 min of reperfusion and are expressed as the means ± SEM. Ctr, control; PPC, pacing postconditioning; GD, gestation day. ^*∗*^*P* \< 0.01 compared to the respective control. ^†^*P* \< 0.01 compared to the ischemic period.](CRP2019-3403959.006){#fig6}

![Effects of comorbidities on PPC-induced cardiac protection. Schematic representation summarizing the results of the study.](CRP2019-3403959.007){#fig7}

###### 

Effects of ischemia-reperfusion and PPC on heart contractility.

  Treatment               +dP/dt         −dP/dt                             
  ----------------------- -------------- ------------------- -------------- -------------------
  Ctr male                54.32 ± 3.48   58.89 ± 6.94        49.22 ± 2.09   48.28 ± 3.77
  Ctr male + PPC          50.66 ± 3.55   80.45 ± 4.64^*∗*^   50.13 ± 3.83   80.22 ± 2.48^*∗*^
  Ctr old male            55.30 ± 4.31   56.13 ± 4.53        56.32 ± 4.13   49.53 ± 3.94
  Old male + PPC          49.78 ± 1.86   49.66 ± 2.88        58.86 ± 3.81   61.51 ± 4.33
  Ctr female              54.59 ± 4.41   48.16 ± 6.70        52.45 ± 3.27   50.81 ± 3.99
  Ctr female + PPC        50.66 ± 3.55   75.75 ± 3.43^*∗*^   50.13 ± 3.83   80.22 ± 2.48^*∗*^
  Ctr old female          49.22 ± 2.09   48.28 ± 3.77        60.22 ± 4.14   59.91 ± 5.43
  Ctr old female + PPC    56.08 ± 3.10   69.08 ± 4.75^*∗*^   56.62 ± 4.65   68.56 ± 2.77^*∗*^
  Ctr male                59.31 ± 6.34   64.88 ± 4.99        54.54 ± 4.94   50.74 ± 3.07
  Ctr male + PPC          50.66 ± 4.10   81.27 ± 3.02^*∗*^   52.57 ± 2.46   78.81 ± 3.66^*∗*^
  Ctr LVH male            66.45 ± 5.47   76.57 ± 4.43        67.44 ± 2.43   76.99 ± 3.53
  LVH male + PPC          69.32 ± 6.87   68.64 ± 2.78        68.74 ± 8.50   80.72 ± 5.22
  Ctr female              53.82 ± 6.07   55.56 ± 6.25        54.77 ± 3.29   57.84 ± 5.05
  Ctr female + PPC        62.63 ± 4.68   82.08 ± 2.96^*∗*^   61.76 ± 4.05   78.49 ± 4.64^*∗*^
  Ctr LVH female          68.20 ± 7.11   72.83 ± 6.33        73.27 ± 9.72   71.35 ± 4.48
  LVH female + PPC        56.99 ± 7.82   85.57 ± 7.14^*∗*^   52.61 ± 3.51   70.46 ± 6.42^*∗*^
  Ctr diabetic male       59.31 ± 6.34   64.88 ± 4.99        54.54 ± 4.94   50.74 ± 3.07
  Diabetic male + PPC     55.86 ± 4.02   59.29 ± 8.94        49.06 ± 2.68   47.53 ± 4.77
  Ctr diabetic female     58.98 ± 5.09   55.04 ± 8.03        56.15 ± 3.46   58.39 ± 4.79
  Diabetic female + PPC   53.05 ± 4.18   59.70 ± 8.90        47.84 ± 2.02   48.16 ± 4.68
  Ctr female 19 GD        49.45 ± 2.59   63.63 ± 1.81        51.97 ± 1.24   65.17 ± 0.66
  Female 19 GD + PPC      50.46 ± 3.36   72.59 ± 1.38^*∗*^   55.97 ± 1.57   71.27 ± 1.29^*∗*^
  Ctr female 21 GD        47.19 ± 2.04   59.78 ± 1.46        47.84 ± 1.69   64.00 ± 0.43
  Female 21 GD + PPC      49.79 ± 2.09   72.80 ± 1.88^*∗*^   50.95 ± 3.28   71.19 ± 0.63^*∗*^

Ctr: control; PPC: pacing postconditioning; LVH: left ventricle hypertrophy; GD: gestation day. ^*∗*^*P* \< 0.01 compared to the respective control.

###### 

Effects of ischemia-reperfusion and PPC on cardiac enzymes levels.

  Treatment               CK IU/L             *P* value   LDH IU/L            *P* value
  ----------------------- ------------------- ----------- ------------------- -----------
  Ctr male                21.32 ± 1.84        ---         20.73 ± 1.37        ---
  Ctr male + PPC          9.41 ± 1.87^*∗*^    0.001       7.94 ± 1.83^*∗*^    0.001
  Ctr old male            21.13 ± 1.12        ---         18.62 ± 2.10        ---
  Old male + PPC          20.23 ± 1.43        0.231       18.42 ± 2.02        0.411
  Ctr female              20.13 ± 1.82        ---         18.93 ± 1.11        ---
  Ctr female + PPC        10.21 ± 1.71^*∗*^   0.001       9.95 ± 1.64^*∗*^    0.001
  Ctr old female          20.13 ± 1.86        ---         16.47 ± 1.82        ---
  Old female + PPC        10.53 ± 1.24^*∗*^   0.001       9.03 ± 1.65^*∗*^    0.001
  Ctr male                23.41 ± 2.13        ---         19.21 ± 1.98        ---
  Ctr male + PPC          10.23 ± 1.43^*∗*^   0.001       8.11 ± 2.13^*∗*^    0.001
  Ctr LVH male            23.54 ± 2.63        ---         16.22 ± 1.43        ---
  LVH male + PPC          21.39 ± 2.02        0.315       17.53 ± 1.45        0.314
  Ctr female              20.85 ± 1.93        ---         17.97 ± 1.36        ---
  Ctr female + PPC        10.98 ± 1.61^*∗*^   0.001       9.14 ± 1.82^*∗*^    0.001
  Ctr LVH female          22.10 ± 1.83        ---         16.31 ± 1.92        ---
  LVH female + PPC        9.14 ± 1.19^*∗*^    0.001       10.63 ± 1.92^*∗*^   0.01
  Ctr diabetic male       23.75 ± 2.13        ---         17.52 ± 1.61        ---
  Diabetic male + PPC     21.72 ± 1.71        0.524       19.27 ± 2.13        0.243
  Ctr diabetic female     20.63 ± 2.85        ---         18.92 ± 1.62        ---
  Diabetic female + PPC   21.31 ± 1.86        0.463       18.26 ± 1.23        0.217
  Ctr female 19 GD        20.42 ± 1.66        ---         16.24 ± 1.23        ---
  Female 19 GD + PPC      9.92 ± 1.12^*∗*^    0.001       8.31 ± 1.14^*∗*^    0.001
  Ctr female 21 GD        21.33 ± 1.62        ---         17.24 ± 1.38        ---
  Female 21 GD + PPC      9.87 ± 1.95^*∗*^    0.001       8.05 ± 1.23^*∗*^    0.001

CK: creatine kinase; LDH: lactate dehydrogenase; Ctr: control; PPC: pacing postconditioning; LVH: left ventricle hypertrophy; GD: gestation day. ^*∗*^*P* \< 0.001 compared to the respective control.

[^1]: Academic Editor: Vincenzo Russo
